TECH

Bio-Techne Corporation

Next est. report 2026-11-04 · BMO

Genomics '25: Genomics Tools & AutomationMedTech Long '26: Life Science Tools & Bioprocessing MedTech Short '25: Heavy China Exposure

Loading…

Loading chart…

Overview

Bio-Techne Corporation provides life science reagents, instruments, and services for global research, diagnostics, and bioprocessing markets. Its Protein Scienc

Bio-Techne Corporation provides life science reagents, instruments, and services for global research, diagnostics, and bioprocessing markets. Its Protein Sciences segment (72% of Q3 FY26 revenue) offers biological reagents and analytical tools. The Diagnostics and Spatial Biology segment (28%) focuses on diagnostic products and spatial analysis. Merck KGaA agreed to acquire Bio-Techne in June 2026, with closing expected by early 2027.

Search Keywords Brand Product

R&D Systems
Bio-Techne Spatial Biology
Bio-Techne Diagnostics
RNAscope kits
COMET platform
Ella immunoassay
Maurice platform
G-Rex bioreactors
GMP proteins
antibodies
reagents
ProPak
life science tools
proteomic analysis
spatial biology
cell therapy development
drug discovery
clinical diagnostics
bioprocessing
AI in biotech
biotech funding
academic research

Search Keywords Event Phrases

Bio-Techne earnings
Bio-Techne Q3 2026
Bank of America Healthcare Conference
Jefferies Healthcare Conference

Search Keywords Policy Regulatory

FDA Fast Track Designation
CE-IVD marking
NIH budget

What They Do (Plain English & Analogies): Bio-Techne Corporation provides specialized tools and ingredients for scientists and medical professionals. Imagine researchers developing new medicines or diagnostic tests; Bio-Techne supplies them with crucial biological components, like highly specific proteins and antibodies, which are essential for understanding diseases and creating new treatments. They also offer advanced analytical machines that can quickly and accurately examine these biological parts, accelerating the discovery process. For example, they have tools that can map out what's happening inside cells and tissues in great detail, which is vital for developing personalized therapies. Additionally, they produce quality control products that hospitals use to ensure their laboratory equipment provides accurate test results.
Very Brief History: Bio-Techne Corporation was incorporated in 1976 as Techne Corporation. It expanded significantly through innovation and strategic acquisitions, including R&D Systems in 2006, ProteinSimple in 2014, Advanced Cell Diagnostics in 2016, and Lunaphore in 2023. In November 2014, the company rebranded to Bio-Techne Corporation to better reflect its broader portfolio of life science tools and diagnostics solutions.
"Street Stereotype": Bio-Techne is generally perceived by investors and analysts as a company highly leveraged to early-stage biotech research and development (R&D), primarily through its premium protein, antibody, and reagent portfolios. It is often considered a rapid-response indicator for a broader recovery in biotech funding.
Subsidiaries On Linked In*: Advanced Cell Diagnostics (ACD) — Leader in molecular pathology, developing RNAscope technology; operates as an independent subsidiary of Bio-Techne.; LinkedIn: advanced-cell-diagnostics
Novus Biologicals — Specializes in antibodies and biological reagents; became part of the Bio-Techne family in 2014.; LinkedIn: novus-biologicals
ProteinSimple — Offers proteomic analytical tools and instruments; its brand is now integrated into the R&D Systems brand.; LinkedIn: proteinsimple
R&D Systems — Comprehensive portfolio of research reagents and tools; a trademark of Bio-Techne Corporation.; LinkedIn: r-d-systems
Lunaphore Technologies SA — Developer of fully automated spatial biology solutions, including the COMET platform; acquired by Bio-Techne in 2023.; LinkedIn: lunaphore-technologies-sa
Wilson Wolf Manufacturing — Manufacturer of G-Rex single-use bioreactors; Bio-Techne holds a 20% ownership stake with an option to acquire the remainder.; LinkedIn: wilson-wolf-manufacturing
Tocris Bioscience — Specializes in high-performance life science reagents; part of the Bio-Techne family.; LinkedIn: tocris-bioscience
Asuragen — A Bio-Techne brand, acquired in 2021, focused on molecular diagnostics kits and products.; LinkedIn: asuragen
Customer Sectors & Example Clients: Bio-Techne serves a diverse range of customer sectors, including large pharmaceutical companies, emerging biotech companies, academic institutions, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs). Their products are utilized by clients involved in cell therapy development (including those with FDA Fast Track Designation), neurodegeneration research, and biopharma manufacturing workflows. An example of a collaboration mentioned is with Providence Health and Microsoft, where Bio-Techne's Spatial Biology platform, COMET, was used for the GigaTIME AI framework.
New Customers / Segments They'Re Targeting: Bio-Techne is targeting customers across the entire research to clinical continuum, simplifying engagement through its new brand alignment. Specifically, with the CE-IVD marking for its Ella platform, the company is enabling hospitals, clinical laboratories, and other European organizations to use Ella for clinical applications, in-house test development, clinical trials, or other translational activities. The RNAscope portfolio is also seeing increasing use in clinical diagnostic applications in the U.S. In China, they are seeing increasing demand from biopharma and CRO customers focused on antibody drug conjugates, cell therapy, and autoimmune disorders. The company is also enhancing the visibility of its solutions across digital and AI-driven platforms to better serve customers leveraging AI in drug discovery.
Supply Chain And Sourcing Geographies: The provided transcript does not explicitly detail Bio-Techne's specific supply chain or sourcing geographies for its products and components. However, the company maintains a global footprint with manufacturing sites, research and development centers, and customer support offices worldwide. Bio-Techne has manufacturing operations in North America, the U.K., and China. A new distribution hub in Dublin, Ireland, strengthens its EMEA supply chain operations. The company uses a wide variety of raw materials and components, including electronic components, chemicals, and biological materials, and employs techniques like safety stock and multiple supply sources to address potential disruptions.
Sales Geographies And Expansion Plans: Bio-Techne currently sells its products across various global geographies, including the Americas (specifically North America), Europe, and Asia (with a strong focus on China and the broader APAC region). Management has indicated plans for continued momentum and strengthening in the China end market, evidenced by the installation of the first COMET system in the region. The company also has operations and managed distribution in virtually every country in the Asia-Pacific region, with strong results in Korea, India, and Australia. Bio-Techne sells directly to customers and through distributors, including a distribution agreement with Thermo Fisher Scientific.
How Key Themes May Help/Hurt: Bio-Techne is significantly impacted by the 'MedTech Long '26: Life Science Tools & Bioprocessing' theme. The surging demand for complex biologics and GLP-1 therapeutics benefits Bio-Techne through its GMP protein portfolio, essential for cell therapy and advanced therapeutics, and its Maurice platform for biopharma manufacturing quality control. The anticipated sustained recovery in biotech venture capital funding is a direct positive for Bio-Techne's core reagents and instruments, especially as emerging biotech spending is expected to rebound. Accelerated pharma reshoring and increased CDMO outsourcing also fuel demand for Bio-Techne's reagents and analytical platforms used in manufacturing workflows. Conversely, the persistent lag in translating improving biotech funding into actual customer spending, particularly in early-stage discovery, is a current headwind for Bio-Techne's emerging biotech segment. While the U.S. academic market has stabilized, its 'frail' nature means it's not yet a strong growth driver. However, the theme's bear point regarding geopolitical tensions and weakness in the China market is currently not impacting Bio-Techne negatively, as the company reports strong and continued positive growth in China.

3 Main Long-Term Bull Details

Leadership in High-Growth Platforms: Bio-Techne holds strong positions in rapidly expanding areas like Spatial Biology (COMET, RNAscope) and Proteomic Analysis (Ella, Maurice), which are crucial for generating content-rich biological data sets increasingly demanded by researchers and for AI-driven drug discovery.
Foundational Role in Advanced Therapeutics: The company's differentiated portfolio of GMP reagents, instruments, and analytical technologies is essential for the development and manufacturing of advanced therapeutics, including cell and gene therapies, supported by robust underlying growth in its GMP protein revenue and strategic investment in Wilson Wolf.
Proprietary Data and AI Integration: Bio-Techne's competitive advantage is reinforced by its AI models, trained on five decades of proprietary data, which enable the design of novel proteins and enhance productivity, positioning the company to capitalize on the accelerating influence of AI in drug discovery.

3 Main Long-Term Bear Details

Sensitivity to Biotech Funding Cycles and Spending Lags: Bio-Techne's significant exposure to early-stage biotech R&D makes its performance vulnerable to the inherent volatility of biotech funding and the typical 2-3 quarter lag between funding availability and actual customer spending, which can lead to revenue softness, particularly in early-stage discovery.
Customer Concentration and Order Timing Volatility: The company's reliance on large customers, particularly in cell therapy and diagnostics, can result in lumpiness and temporary headwinds in quarterly revenue due to order timing fluctuations, as seen with FDA Fast Track designated cell therapy customers and a large OEM commercial supply order.
Frail Academic Market Recovery: Although the U.S. academic market has returned to low single-digit growth, management describes it as 'frail' and not indicative of a V-shaped recovery, suggesting persistent budgetary constraints and cautious spending that could temper overall growth.

Competitors And Differentiation: Bio-Techne operates in a competitive landscape, with competitors mentioned including Cell Signaling Technology, PerkinElmer, Vanda Pharmaceuticals, MilliporeSigma, Cytiva, Abcam, Merck Millipore, Bruker, Agilent Technologies, Bio-Rad Laboratories, Charles River Laboratories International, and Danaher. Bio-Techne differentiates itself through several key aspects: its AI models, trained on five decades of proprietary data, create a meaningful competitive moat for designing novel proteins. Its core reagent and assay portfolio is known for differentiated performance in bioactivity, lot-to-lot consistency, and reproducibility. The Ella platform offers rapid, highly reproducible protein quantification with ultrasensitive capabilities for neurological biomarker analysis. The Maurice platform is increasingly embedded in biopharma manufacturing for faster and more consistent assessment of protein attributes. The company also holds a leadership position in in situ hybridization and mid-plex multiomic applications through its Spatial Biology portfolio, including the COMET platform. Additionally, Wilson Wolf, in which Bio-Techne holds a stake, manufactures the market-leading G-Rex single-use bioreactors.
Recent Performance & What The Market'S Focused On: In the third quarter of fiscal year 2026, Bio-Techne reported a 2% organic revenue decline, though underlying organic revenue growth was 2% when excluding order timing impacts from two cell therapy customers with FDA Fast Track Designation and a large OEM commercial supply order. Adjusted EPS was $0.53, down $0.03 year-over-year. The Protein Sciences segment saw a 4% organic revenue decline (2% underlying growth), while Diagnostics and Spatial Biology grew 3% organically. Large pharma customers delivered double-digit growth, U.S. academia returned to low single-digit growth, and China achieved positive organic growth for the fourth consecutive quarter. However, emerging biotech revenues declined high single digits, which was a key surprise. For the fourth quarter of fiscal year 2026, Bio-Techne expects approximately flat organic growth, or low single-digit underlying growth excluding cell therapy headwinds. The market is primarily focused on the timing and extent of the recovery in emerging biotech spending, which is considered the 'biggest swing factor' for growth acceleration in fiscal year 2027. Investors are also tracking whether Bio-Techne can achieve its anticipated mid-single-digit growth in fiscal year 2027 and the continued strong performance of its Spatial Biology (COMET) and GMP protein portfolios.

Revenue Segments And Estimated Mix: Protein Sciences — Mix: ~72.5%; Source: Q3 FY26 transcript; Trend: Organic revenue declined 4% (underlying growth 2% excluding specific customer timing impacts).
Diagnostics and Spatial Biology — Mix: ~27.5%; Source: Q3 FY26 transcript; Trend: Organic revenue grew 3%.
Product Brands: R&D Systems
Bio-Techne Spatial Biology
Bio-Techne Diagnostics
RNAscope
COMET
Ella
Maurice
G-Rex
Novus Biologicals
Tocris Bioscience
SPYRE antibody panel kits
HORIZON image analysis software
LabSat
ProximityScope
ProPak
Asuragen
Bionostics
Cliniqa
RNA Medical

Bull / Bear Details

Bio-Techne is poised for a fiscal year 2027 acceleration, driven by robust demand from large pharma, stabilizing U.S. academia, and strong growth in China. Stra

Thesis

Bio-Techne is poised for a fiscal year 2027 acceleration, driven by robust demand from large pharma, stabilizing U.S. academia, and strong growth in China. Strategic investments in Spatial Biology and GMP proteins, coupled with AI integration, provide durable tailwinds. While emerging biotech spending lags funding, its anticipated recovery in late 2026, alongside the roll-off of temporary headwinds, supports a bullish outlook for mid-single-digit growth. (August 10, 2026)

Bull case

Bio-Techne's Spatial Biology portfolio, particularly the COMET platform, and GMP protein portfolio are delivering exceptional growth (65% and nearly 50% respectively, excluding specific customer timing). These high-growth areas, along with strategic brand alignment and AI integration in drug discovery, position the company for sustained innovation and market leadership in critical life science applications.
Despite current softness, improving biotech funding is expected to translate into increased customer spending by fiscal year 2027, driving a broader market recovery. This, combined with sustained double-digit growth from large pharmaceutical customers and stabilizing U.S. academic demand, provides a diversified and resilient revenue base for future growth.
Bio-Techne continues to demonstrate strong momentum in the China market, achieving positive organic growth for the fourth consecutive quarter, indicating successful regional expansion and increasing demand from biopharma and CRO customers. The company also maintains sector-leading profitability with disciplined expense management, improving adjusted operating margins sequentially.

Bear case

Emerging biotech spending continues to decline (high single digits), lagging significantly behind the rebound in overall biotech funding. This is exacerbated by a shift in funding towards late-stage clinical development, impacting Bio-Techne's core early-stage reagent portfolio and delaying a broader recovery in this crucial end market.
The company experienced significant revenue headwinds in Q3 FY26 due to order timing from two large cell therapy customers with FDA Fast Track designations and a large OEM commercial supply order. While these are expected to moderate, they highlight vulnerability to large customer ordering patterns and can obscure underlying performance.
Although the U.S. academic market has returned to low single-digit growth, management describes it as "frail" and not indicative of a V-shaped recovery. Persistent budgetary constraints and cautious spending in this sector, alongside potential competitive pressures in the core reagent business, could temper overall growth.

Bull / Bear Case

Bear Case: The primary bear case centers on the limited upside for new investors due to the announced acquisition by Merck KGaA at a fixed price of $73 per share, with the stock currently trading very close to this offer. This acquisition, while de-risking, is subject to regulatory and shareholder approvals, and any delays or failure to close could introduce significant uncertainty. Operationally, emerging biotech spending continues to decline (high single digits), lagging significantly behind funding rebounds, impacting Bio-Techne's core early-stage reagent portfolio. The U.S. academic market, while showing low single-digit growth, is described as 'frail' by management, suggesting a slow recovery. Furthermore, current valuation metrics, such as a trailing P/E of over 100x and an EV/EBITDA of 30x-44x, are significantly above industry averages, and a discounted cash flow analysis suggests the stock is overvalued by more than 21% at its current price.
Bull Case: Bio-Techne is poised for a strong fiscal year 2027, driven by robust demand from large pharmaceutical customers, which has shown double-digit growth for six consecutive quarters. The company's high-growth platforms, including Spatial Biology (COMET platform growing over 65%) and the GMP protein portfolio (nearly 50% growth excluding specific customer timing), are leading indicators for market recovery and are strategically aligned with future drug discovery trends. Additionally, the U.S. academic market is stabilizing, and China continues its positive organic growth momentum for the fourth consecutive quarter. The integration of AI, trained on five decades of proprietary data, further enhances Bio-Techne's competitive moat and productivity, positioning it for sustained innovation and market leadership in critical life science applications. The anticipated recovery in emerging biotech spending in fiscal year 2027, following recent funding rebounds, is expected to accelerate overall growth.
More Compelling & Why: Bear. The current stock price of approximately $72.09 - $72.10 offers negligible upside to the $73 per share acquisition price by Merck KGaA. For new investors, the strongest argument for the bear case is the extremely limited return potential given the fixed acquisition price, with the primary risk being the deal's failure or delay. My view would flip if the acquisition were to fall through and the stock price were to drop significantly below the $73 offer, creating a substantial arbitrage opportunity or a more attractive valuation based on fundamentals.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Management's official organic growth guidance for fiscal year 2027	This guidance provides a forward-looking view of the company's expected top-line performance, reflecting management's confidence in market recovery and strategic execution, directly impacting investor sentiment.	The specific organic growth percentage range provided by management for fiscal year 2027 during the Q4 FY26 earnings call.	Bullish if FY27 organic growth guidance is at or above mid-single digits (e.g., 5% or higher). Bearish if guidance is below mid-single digits (e.g., <3%) or if management expresses significant caution.	Bio-Techne's Q4 FY26 earnings call and press release (expected around August 11-12, 2026).	Analyst consensus estimates for FY27 revenue growth (available on financial news sites after guidance is released).	Bloomberg Terminal / Refinitiv Eikon: Detailed consensus estimates, analyst reports, earnings transcripts; FactSet: Financial models, estimates, and company data.
Sustained high organic revenue growth in the GMP protein portfolio, excluding specific cell therapy customer timing impacts	This portfolio is foundational for advanced therapeutics like cell therapies. Strong growth indicates Bio-Techne's leadership and successful execution in a strategic, high-growth market, validating its long-term potential.	Organic revenue growth rate of the GMP protein portfolio in subsequent earnings reports, specifically adjusted for any large customer timing impacts. Also, watch for the 12-month trailing growth for cell therapy, with a target of at least 20%.	Bullish if underlying GMP protein growth remains strong (e.g., >40% year-over-year) and the 20% trailing 12-month target for cell therapy is met or exceeded. Bearish if underlying growth significantly decelerates (e.g., below 20% year-over-year).	Bio-Techne's quarterly earnings calls and press releases (next expected Q4 FY26 earnings call around August 11-12, 2026).	Industry news on cell and gene therapy clinical trial advancements (e.g., Fierce Biotech, Endpoints News); government databases for new FDA Fast Track designations for cell therapies (FDA website).	EvaluatePharma: Cell and gene therapy pipeline analysis, clinical trial progression, market size forecasts; DRG Abacus: Market share and competitive intelligence for bioprocessing reagents.
An inflection point in organic revenue growth from emerging biotech customers, translating recent funding into increased spending	Emerging biotech is identified as the 'biggest swing factor' for Bio-Techne's growth acceleration. A recovery here is crucial for improving overall revenue and investor sentiment, especially for the core reagent portfolio.	Organic revenue growth from emerging biotech customers in Q4 FY26 and Q1 FY27 earnings reports. Management expects a meaningful uptick in calendar H2 2026 (Bio-Techne's Q1 FY27).	Bullish if emerging biotech revenue growth turns positive (low single digits or higher) in Q4 FY26 or Q1 FY27. Bearish if it remains negative high single digits or declines further in Q4 FY26.	Bio-Techne's quarterly earnings calls and press releases.	PitchBook-NVCA Venture Monitor: Global Biotech Venture Capital Funding (Q2 2026 data expected late July - August 2026); Fierce Biotech / Endpoints News: News on biotech funding rounds, M&A, IPOs.	PitchBook / Crunchbase: Detailed biotech funding rounds, deal sizes, investor activity, company profiles; Preqin: Private capital market data, including venture capital.
Continued strong order growth and efficient conversion of the record backlog for the COMET Multiomic Spatial Platform	COMET is a key growth driver in the high-demand Spatial Biology market. Sustained growth and backlog conversion demonstrate market adoption and Bio-Techne's ability to capitalize on AI-driven drug discovery trends.	COMET platform organic revenue growth rate (Q3 FY26: >65%), and management commentary on the size and conversion efficiency of the backlog in subsequent earnings calls.	Bullish if COMET platform growth remains strong (e.g., >50% year-over-year) and backlog continues to be robust or converts efficiently into revenue. Bearish if growth significantly decelerates (e.g., below 30% year-over-year) or backlog shrinks without corresponding revenue recognition.	Bio-Techne's quarterly earnings calls and press releases.	Google Trends: 'Bio-Techne COMET' or 'spatial biology platform' search volume; industry news on spatial biology advancements and competitive product launches (e.g., GenomeWeb, The Scientist).	AlphaSense / Tegus: Transcripts of competitor earnings calls for spatial biology market commentary, expert interviews; SimilarWeb: Web traffic to Bio-Techne's spatial biology product pages and competitor sites.
Continued positive organic growth and signs of acceleration in the U.S. academic end market	The U.S. academic market has shown signs of stabilization after a period of softness. Continued improvement or acceleration would provide a more resilient revenue base and reduce reliance on other volatile segments.	Organic revenue growth from the U.S. academic market in subsequent earnings reports. Look for sustained low single-digit growth or an acceleration to mid-single digits.	Bullish if U.S. academic market growth continues to be positive and shows signs of acceleration (e.g., mid-single digits). Bearish if it reverts to decline or remains flat (0% growth).	Bio-Techne's quarterly earnings calls and press releases.	NIH budget updates and grant activity (grants.nih.gov, NIH Reporter); USASpending.gov: Federal research grant awards (filter by agency, recipient).	Academic institution budget reports (where publicly available, though often delayed); Scopus/Web of Science: Research publication trends, indicating activity levels and funding impact; GovWin IQ: Government contract awards and spending data.

Key Reported Metrics, Reratings Triggers & Results3 rows

This high-growth area is critical for advanced therapeutics like cell therapies, indicating underlying strength and successful execution in a strategic market.

Last reported · 2026-08-12

Key reported metrics			Rerating thresholds
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date
GMP Protein Portfolio Revenue Growth (excluding specific cell therapy customers)	nearly 50%	This high-growth area is critical for advanced therapeutics like cell therapies, indicating underlying strength and successful execution in a strategic market. Sustained strong growth here is vital for future performance.	For Bio-Techne Corporation's stock to re-rate higher, the GMP Protein Portfolio Revenue Growth (excluding specific cell therapy customers) metric needs to demonstrate continued exceptional strength by maintaining year-over-year growth above 40% for the upcoming Q4 FY26 earnings report. Sustaining growth significantly above the previously identified bullish threshold of 30% and close to the prior quarter's nearly 50% would be a key indicator.	Sustained high growth in the GMP protein portfolio validates Bio-Techne's leadership in a critical, high-growth area for advanced therapeutics like cell and gene therapies. This performance reinforces the strategic rationale for the recent acquisition by Merck KGaA, demonstrating enduring value and strong execution, which could bolster investor confidence in the deal's successful completion and the company's long-term prospects.	2026-08-12
Overall Organic Revenue Growth	-2%	This is the primary indicator of Bio-Techne's top-line performance. Management's guidance for flat organic growth in the upcoming quarter and expectations for mid-single-digit growth in FY27 make this a key watch for market recovery.	Overall Organic Revenue Growth needs to hit positive low single-digits (e.g., 1-3% year-over-year) for Q4 FY26.	Achieving positive low single-digit organic revenue growth would signal a crucial inflection point, validating management's thesis for fiscal year 2027 acceleration. It would indicate a recovery in key end markets, particularly emerging biotech, and demonstrate the effectiveness of strategic growth platforms, thereby boosting investor confidence and potentially rerating the stock higher.	2026-08-12
Emerging Biotech Revenue Growth	declined high single digits %	This metric is the "biggest swing factor" for Bio-Techne's growth acceleration into fiscal year 2027. Its recovery, driven by recent funding rebounds, is crucial for overall revenue improvement and investor sentiment.	For Bio-Techne's stock to rerate higher, Emerging Biotech Revenue Growth needs to turn positive (low single digits or higher) in the Q4 FY26 earnings report. This would exceed management's implied expectation of a 'flattish' performance for this segment in Q4 FY26 and signal an earlier-than-anticipated recovery from the current high single-digit decline.	Emerging Biotech Revenue Growth is considered the 'biggest swing factor' for Bio-Techne's growth acceleration in fiscal year 2027. A positive inflection point in Q4 FY26 would demonstrate that the rebound in biotech funding is translating into customer spending sooner than anticipated, validating the bullish investment thesis for FY27 and improving investor sentiment regarding the company's core early-stage reagent portfolio.	2026-08-12

Key Questions

Will the recent rebound in biotech funding finally translate into an inflection point for emerging biotech customer spending in Q4 FY26, or will the lag persist

Will the recent rebound in biotech funding finally translate into an inflection point for emerging biotech customer spending in Q4 FY26, or will the lag persist, keeping Bio-Techne's overall growth flat as anticipated?

Question 2: Can Bio-Techne achieve its anticipated 'approximately flat' organic growth in Q4 FY26, excluding the moderating cell therapy headwinds, and effectively position itself for the expected mid-single-digit acceleration in fiscal year 2027?
Question 3: Will the exceptional growth rates in Bio-Techne's Spatial Biology (COMET) and GMP protein portfolios remain sustainable and continue to serve as reliable leading indicators for a broader market recovery, particularly in emerging biotech?

Earnings Transcript SummaryTable

2026-05-06 · 2026Q3 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Operational and Commercial Execution in a Dynamic Market: Management emphasized executing with discipline in an 'uneven end market environment' and focusing on what they can control, including operational and commercial execution. They highlighted sustained strength from large pharmaceutical customers and improving trends in U.S. academia, while acknowledging softness in emerging biotech. 2. Profitability and Disciplined Expense Management: Management remained highly focused on profitability, noting that adjusted operating margin in Q3 was 34.2%, representing a 310 basis point sequential improvement over fiscal Q2. They also mentioned disciplined expense management and structural streamlining. 3. Investing in Strategic Growth Platforms and Innovation: Management is actively investing in and seeing strong performance from key growth areas such as Spatial Biology (mid-teens growth, record backlog for COMET), GMP protein portfolio (nearly 50% growth excluding specific customers), and Proteomic Analysis. They also highlighted leveraging AI internally and for customers in drug discovery.	Call Takeaway & ToneThe overall takeaway of the call is one of cautious optimism for Bio-Techne. While the company faced a challenging and mixed end-market environment in Q3 2026, resulting in a 2% organic revenue decline, management highlighted strong execution and encouraging underlying trends. The tone was generally positive regarding the long-term outlook, particularly for fiscal 2027, but cautious about the immediate next quarter (Q4 2026) due to the continued lag in emerging biotech spending. Key themes included the divergence between strong large pharma demand and soft emerging biotech, stabilization in U.S. academia, continued momentum in China, and robust growth in strategic areas like Spatial Biology and GMP proteins (excluding specific customer timing impacts). Management emphasized disciplined operations, profitability, and strategic investments in growth platforms, positioning the company for an anticipated acceleration in the next fiscal year.	Prior Quarter'S Y/Y Growth By SegmentIn Q2 2026, Bio-Techne's overall organic revenue growth was flat year-over-year. The Protein Sciences segment organic revenue declined 1% (or grew 4% excluding cell therapy timing impacts). The Diagnostics and Spatial Biology segment organic revenue grew 3%.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Emerging Biotech Performance and Recovery Timeline: Analysts pressed on the surprising step-down in emerging biotech revenue (down high single digits in Q3 vs. mid-single digits in Q2) despite improving funding. Management responded that while funding has rebounded meaningfully, particularly in late-stage biotech, early-stage biotech funding (which impacts their core reagents) was down. They noted increased engagement and dialogue but are cautiously forecasting flattish performance for Q4, expecting a more meaningful uptick in fiscal year 2027 due to the typical 2-3 quarter lag between funding and spending. 2. Outlook for Fiscal 2027 and Potential for Mid-Single-Digit Growth: Analysts questioned if Bio-Techne could still achieve mid-single-digit growth in fiscal 2027 given the current market challenges. Management expressed confidence, stating they would be 'disappointed if we didn't do at least mid-single-digit growth' in FY27, citing normalizing markets, company-specific headwinds rolling off, and easier year-over-year comparisons. They pointed to strong performance in proteomic analysis and spatial biology in U.S. academia as early indicators of market recovery. 3. Core RUO Reagent Business Performance and Competitive Dynamics: An analyst asked about the softness in the RUO reagent business and whether it indicated market share loss, given competitors showing signs of recovery. Management clarified that a large OEM commercial supply order timing issue impacted the Q3 numbers for core reagents. They stated that excluding this impact, their proteins and antibodies combined grew low single digits, and they are confident in their competitive position, especially considering their strong double-digit growth comparables from the prior year.	Revenue SegmentsOverall organic revenue declined 2%. Protein Sciences segment organic revenue declined 4% (or grew 2% excluding cell therapy and OEM commercial supply timing impacts). Diagnostics and Spatial Biology segment organic revenue grew 3%. Within Protein Sciences, GMP protein portfolio grew nearly 50% year-over-year (excluding 2 fast track cell therapy customers), Proteomic Analysis franchise delivered mid-single-digit growth, and the core reagent and assay portfolio declined mid-single digits (or low single digits excluding OEM commercial supply customer). Within Diagnostics and Spatial Biology, Spatial Biology portfolio delivered mid-teens growth, COMET Multiomic Spatial Platform grew over 65%, RNAscope portfolio increased high single digits, and Bio-Techne Diagnostics declined low single digits. Geographically, Americas declined low single digits, Europe achieved mid-single-digit growth, Asia delivered low single-digit growth, and China achieved positive organic growth for the fourth consecutive quarter with low single-digit growth. By end market, large pharma grew low double digits, emerging biotech declined high single digits, and academia grew low single digits.

Transcript Tidbits2 rows

2026-05-06

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketBio-Techne announced a strategic brand alignment to streamline its portfolio from 10 brands to 3, simplifying customer engagement across the research to clinical continuum and enhancing visibility on digital and AI-driven platforms. The company achieved CE-IVD marking for its Ella platform, enabling its use for clinical applications in Europe. The first COMET system was installed in China, marking an important milestone for demand in the region. RNAscope portfolio growth was driven by increased customer adoption in EMEA and Asia, and growing use in clinical diagnostic applications in the U.S.	About CompetitionBio-Techne believes its AI models, trained on 5 decades of proprietary data, create a meaningful competitive moat. When asked about competitors showing recovery in RUO reagents, Bio-Techne stated that after adjusting for a large OEM order timing impact and considering their double-digit growth last year compared to competitors' negative numbers, they are confident they are 'still pretty well off'.	About The Broader IndustryThe end market environment is dynamic and uneven, with sustained strength from large pharmaceutical customers and stable to improving trends in the U.S. academic market, partially offset by continued softness in emerging biotech spending. Biotech funding activity has rebounded meaningfully, with increases of over 90% and 50% in fiscal Q2 and Q3 respectively, which is viewed as a constructive setup for fiscal 2027 due to a typical 2 to 3 quarter lag between funding and spending. The U.S. academic market returned to growth, supported by improvements in NIH outlays, new grant activity, and a 1% increase to the NIH budget. China is experiencing increasing demand from biopharma and CRO customers focusing on antibody drug conjugates, cell therapy, and autoimmune disorders. There has been a mix shift in cell therapy trials globally from gene therapy to cell therapy, benefiting Bio-Techne. The funding mix has shifted, with 82% of funding now going into late-stage clinical development, up from 75%, while early-stage discovery funding has decreased from 25% to 18% of budgets.	Where Things Are HeadedBio-Techne anticipates an ongoing improvement in U.S. academia and an eventual recovery in emerging biotech, positioning the company for a stronger fiscal 2027. The company expects organic growth in the fourth quarter to be approximately flat, with low single-digit underlying growth excluding cell therapy headwinds. This near-term outlook is expected to lead to an acceleration in fiscal 2027 as biotech funding translates into customer spending, academic conditions normalize, and company-specific headwinds roll off. Management would be 'disappointed if we didn't do at least mid-single-digit growth' in fiscal year '27, as indicators point towards gradual market normalization. Bio-Techne expects continued momentum and strengthening in the China end market. The company intends to close the last quarter of the year with approximately 100 basis points of margin expansion over the prior year.	Updates On ThemeLife	Broader Themes EmergingArtificial intelligence (AI) is increasingly influencing both Bio-Techne's internal operations and customer drug discovery. Internally, AI is leveraged to design novel and patentable proteins with enhanced properties. From a customer perspective, AI adoption is accelerating early-stage drug discovery, particularly target discovery, and is viewed as a durable tailwind for spatial biology and proteomic analysis platforms, as well as a downstream demand driver for RUO reagents and assays.	Bullish-Leaning Quotes (Short)Our Spatial Biology portfolio delivered mid-teens growth and exited the quarter with another record backlog for our COMET platform. Our GMP protein portfolio grew nearly 50% year-over-year when excluding the 2 fast track cell therapy customers. Our largest end market, large pharma, delivered its sixth consecutive quarter of double-digit growth. Biotech funding activity has since rebounded meaningfully with estimate increases of more than 90% and 50% in our fiscal Q2 and Q3, respectively. China end market achieved positive organic growth for the fourth consecutive quarter. We are seeing encouraging indicators that point to an ongoing improvement in the U.S. academia and an eventual recovery in emerging biotech, which positions us well for a stronger fiscal 2027. We view the growing demand for content-rich biological data sets as a durable tailwind for both our spatial biology and our proteomic analysis platforms. We'd be disappointed if we didn't do at least mid-single-digit growth because all the indicators are pointing towards a gradual normalization of the market.	Bearish-Leaning Quotes (Short)continued softness in emerging biotech spending, resulting in a 2% organic revenue decline for the quarter. order timing related to 2 cell therapy customers that received FDA Fast Track Designation along with the timing of a large OEM commercial supply order created a 400 basis point headwind in the quarter. In emerging biotech, however, revenues declined high single digits reflecting the typical lag in spending following the funding constraints experienced in the first half of calendar 2025. our core reagent and assay portfolio... declined mid-single digits in the quarter. Academic, we see a slight improvement, and we are excited that we're back in positive territory for the first time. It's still a frail market. It's certainly not going to be a V-shaped recovery, I think. early-stage biotech... that early-stage funding was actually down if you tease that apart. And that is where our surprise came in.

2026-05-06

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketBio-Techne announced a strategic brand alignment to streamline its portfolio from 10 brands down to 3, aiming to simplify customer engagement and enhance visibility on digital and AI-driven platforms. The company achieved CE-IVD marking for its Ella platform, enabling its use for clinical applications in Europe. The first COMET system was installed in China, marking an important milestone for demand in the region. Growth in the RNAscope portfolio was driven by increased customer adoption in EMEA and Asia, as well as growing use in clinical diagnostic applications in the U.S.	About CompetitionBio-Techne believes its AI models, trained on 5 decades of proprietary data, create a meaningful competitive moat. When discussing the softness in the RUO reagent business and competitive readouts, management stated that after adjusting for a large OEM order timing impact and considering their double-digit growth last year compared to competitors' negative numbers, they are confident they are 'still pretty well off'.	About The Broader IndustryThe end market environment is dynamic and uneven, characterized by sustained strength from large pharmaceutical customers and stable to improving trends in the U.S. academic market, partially offset by continued softness in emerging biotech spending. Biotech funding activity has rebounded meaningfully, with estimate increases of more than 90% and 50% in fiscal Q2 and Q3 respectively, which is viewed as a constructive setup for fiscal 2027 due to a typical 2 to 3 quarter lag between funding and spending. The U.S. academic market returned to growth, supported by improvements in NIH outlays, new grant activity, and a 1% increase to the NIH budget. China is experiencing increasing demand from biopharma and CRO customers focused on antibody drug conjugates, cell therapy, and autoimmune disorders. There has been a mix shift in cell therapy trials globally from gene therapy to cell therapy. The funding mix has shifted, with 82% of funding now going into late-stage clinical development (up from 75%), while early-stage discovery funding has decreased from 25% to 18% of budgets.	Where Things Are HeadedBio-Techne anticipates an ongoing improvement in U.S. academia and an eventual recovery in emerging biotech, positioning the company for a stronger fiscal 2027. The company expects organic growth in the fourth quarter to be approximately flat, with low single-digit underlying growth excluding cell therapy headwinds. This near-term outlook is expected to lead to an acceleration in fiscal 2027 as biotech funding translates into customer spending, academic conditions normalize, and company-specific headwinds roll off. Management would be 'disappointed if we didn't do at least mid-single-digit growth' in fiscal year '27, as indicators point towards gradual market normalization. Bio-Techne expects continued momentum and strengthening in the China end market. The company intends to close the last quarter of the year with approximately 100 basis points of margin expansion over the prior year.	Updates On ThemeLife	Broader Themes EmergingArtificial intelligence (AI) is increasingly influencing both Bio-Techne's internal operations and how its customers approach drug discovery. Internally, AI is leveraged to design novel and patentable proteins with enhanced properties. From a customer perspective, AI adoption is accelerating the earliest stages of drug discovery, particularly target discovery, and is viewed as a durable tailwind for spatial biology and proteomic analysis platforms, as well as a downstream demand driver for RUO reagents and assays.	Bullish-Leaning Quotes (Short)Our Spatial Biology portfolio delivered mid-teens growth and exited the quarter with another record backlog for our COMET platform. Our GMP protein portfolio grew nearly 50% year-over-year when excluding the 2 fast track cell therapy customers. Our largest end market, large pharma, delivered its sixth consecutive quarter of double-digit growth. Biotech funding activity has since rebounded meaningfully with estimate increases of more than 90% and 50% in our fiscal Q2 and Q3, respectively. China end market achieved positive organic growth for the fourth consecutive quarter. We are seeing encouraging indicators that point to an ongoing improvement in the U.S. academia and an eventual recovery in emerging biotech, which positions us well for a stronger fiscal 2027. We view the growing demand for content-rich biological data sets as a durable tailwind for both our spatial biology and our proteomic analysis platforms. We'd be disappointed if we didn't do at least mid-single-digit growth because all the indicators are pointing towards a gradual normalization of the market.	Bearish-Leaning Quotes (Short)continued softness in emerging biotech spending, resulting in a 2% organic revenue decline for the quarter. order timing related to 2 cell therapy customers that received FDA Fast Track Designation along with the timing of a large OEM commercial supply order created a 400 basis point headwind in the quarter. In emerging biotech, however, revenues declined high single digits reflecting the typical lag in spending following the funding constraints experienced in the first half of calendar 2025. our core reagent and assay portfolio... declined mid-single digits in the quarter. Academic, we see a slight improvement, and we are excited that we're back in positive territory for the first time. It's still a frail market. It's certainly not going to be a V-shaped recovery, I think. early-stage biotech... that early-stage funding was actually down if you tease that apart. And that is where our surprise came in.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-08-12	Bio-Techne reported Q4 FY26 organic revenue growth of 3% to $321.2 million, surpassing estimates, with adjusted EPS of $0.52 meeting expectations. Diagnostics and Spatial Biology showed strength, but Protein Sciences faced margin pressure. The company is focused on its pending $73/share acquisition by Merck KGaA. The stock's modest 0.24% gain, underperforming SPY's 0.75%, suggests a neutral to slightly cautious market perception, likely influenced by the acquisition and mixed segment performance.	Earnings Transcript	Neutral	https://www.bio-techne.com/investors/financial-results	+0.24% (vs SPY: -0.51%)

Prior Earnings Metrics HistoryTable

Prior earnings scorecards